Lakefront Biotherapeutics (LKFT)
29.70
+0.20
(+0.66%)
USD |
NASDAQ |
Oct 09, 13:46
Lakefront Biotherapeutics Shareholders Equity (Quarterly) : 3.731B for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.731B |
| March 31, 2026 | 3.749B |
| December 31, 2025 | 3.800B |
| September 30, 2025 | 2.875B |
| June 30, 2025 | 3.103B |
| March 31, 2025 | 2.968B |
| December 31, 2024 | 3.000B |
| September 30, 2024 | 3.195B |
| June 30, 2024 | 3.119B |
| March 31, 2024 | 3.127B |
| December 31, 2023 | |
| September 30, 2023 | 2.776B |
| June 30, 2023 | 2.819B |
| March 31, 2023 | 2.786B |
| December 31, 2022 | 2.696B |
| September 30, 2022 | 2.636B |
| June 30, 2022 | 2.767B |
| March 31, 2022 | 2.945B |
| December 31, 2021 | 3.006B |
| September 30, 2021 | 3.033B |
| June 30, 2021 | 3.159B |
| March 31, 2021 | 3.175B |
| December 31, 2020 | 3.267B |
| September 30, 2020 | 3.180B |
| June 30, 2020 | 3.115B |
| Date | Value |
|---|---|
| March 31, 2020 | 3.116B |
| December 31, 2019 | 3.228B |
| September 30, 2019 | 2.764B |
| June 30, 2019 | 1.302B |
| March 31, 2019 | 1.320B |
| December 31, 2018 | 1.388B |
| September 30, 2018 | 1.380B |
| June 30, 2018 | 1.034B |
| March 31, 2018 | 1.106B |
| December 31, 2017 | 1.215B |
| September 30, 2017 | 1.226B |
| June 30, 2017 | 1.219B |
| March 31, 2017 | 800.18M |
| December 31, 2016 | 800.24M |
| September 30, 2016 | 796.57M |
| June 30, 2016 | 810.77M |
| March 31, 2016 | 830.21M |
| December 31, 2015 | 396.50M |
| September 30, 2015 | 467.48M |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 11.83B |
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alkermes Plc | 1.809B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Amarin Corp. Plc | 443.62M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 3.831B |
| Total Liabilities (Quarterly) | 100.11M |
| Debt to Equity Ratio | 0.0019 |
| Current Ratio | 32.82 |
| Net Debt Paydown Yield | 0.05% |